Real-world effectiveness of MD1003 (high dose pharmaceutical grade biotin) in patients with progressive MS

被引：0
|
作者：
Faure, J.
Jauffret, J.
Carreau, C. [1 ,2 ]
Legrain, P. [1 ,2 ]
Castex, C. [1 ]
Tourbah, A.
机构：
[1] CHU Reims, Reims, France
[2] Univ Reims, Reims, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P585
引用
下载
收藏
页码：281 / 282
页数：2
相关论文
共 50 条
  • [31] Remotely Monitored Ambulatory Activity Correlates with Disability in Progressive MS: A Baseline Analysis from the SPI2 Phase 3 Clinical Trial of MD1003 (High Dose Pharmaceutical Grade Biotin)
    Block, Valerie J.
    Alexander, Amber
    Papinutto, Nico
    Rajesh, Anand
    Gundel, Tristan
    Gelfand, Jeffrey M.
    Henry, Roland G.
    Sedel, Frederic
    Cree, Bruce A. C.
    NEUROLOGY, 2020, 94 (15)
  • [32] Positive behavioral impact of high dose pharmaceutical grade Biotin, MD1003, in mitochondrial mutant mice with neuron-specific respiratory deficiency
    Campbell, G.
    Dean, J.
    McGill, K.
    Fleming, S.
    Perdomini, M.
    Bernard, D.
    Mahad, D.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 602 - 602
  • [33] Effect of MD1003 (High-Dose Biotin) in spinal progressive multiple sclerosis (MS-SPI): EDSS sub-scores
    Papeix, C.
    Lebrun-Frenay, C.
    Defer, G.
    Labauge, P.
    Ruiz, M.
    Simon, O.
    Tourbah, A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 938 - 939
  • [34] Spinal Cord Area Correlates with Disability and Quality of Life in Progressive MS: A Baseline MRI Analysis from the SPI2 Phase 3 Trial of MD1003 (high dose Pharmaceutical grade Biotin)
    Alexander, Amber M.
    Block, Valerie J.
    Papinutto, Nico
    Rajesh, Anand
    Gundel, Tristan
    Arnold, Douglas
    Sedel, Frederic
    Cree, Bruce A. C.
    Henry, Roland G.
    NEUROLOGY, 2020, 94 (15)
  • [35] Reversal of disability MD1003 in not-active progressive MS real world experience: the French Grand-Est cohort
    Tourbah, A.
    De Seze, J.
    Debouverie, M.
    Berger, E.
    Matthey, G.
    Collongues, N.
    Romain, G.
    Castex, C.
    Moreau, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 757 - 758
  • [36] High Dose Biotin, MD1003, Protects Axons in a Mouse Model of Chronic Spinal Cord Demyelination
    Warrington, Arthur
    Perdomini, Morgane
    Bernard, Delphine
    Rodriguez, Moses
    NEUROLOGY, 2019, 92 (15)
  • [37] Beneficial Effects of High-dose Biotin (MD1003) in Models of X-linked adrenoleukodystrophy
    Fourcade, Stephane
    Parameswaran, Janani
    Goicoechea, Leire
    Launay, Nathalie
    Ruiz, Montserrat
    Sedel, Frederic
    Pujol, Aurora
    NEUROLOGY, 2019, 92 (15)
  • [38] Beneficial effects of high-dose biotin (MD1003) in models of X-linked adrenoleukodystrophy
    Fourcade, S.
    Parameswaran, J.
    Goicoechea, L.
    Launay, N.
    Ruiz, M.
    Sedel, F.
    Pujol, A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 521 - 522
  • [39] MD1003 (High-Dose Biotin) for the treatment of progressive multiple sclerosis: baseline data and results from a cohort of patients included in a early access program
    Brassat, D.
    Hautecoeur, P.
    Durand-Dubief, F.
    Castelnovo, G.
    Derache, N.
    Bourre, B.
    Le Page, E.
    Donze, C.
    Audoin, B.
    Ouallet, J-C.
    Collongues, N.
    Simon, O.
    Brion, G.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 936 - 937
  • [40] MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
    Tourbah, Ayman
    Lebrun-Frenay, Christine
    Edan, Gilles
    Clanet, Michel
    Papeix, Caroline
    Vukusic, Sandra
    De Seze, Jerome
    Debouverie, Marc
    Gout, Olivier
    Clavelou, Pierre
    Defer, Gilles
    Lapland, David-Axel
    Moreau, Thibault
    Labauge, Pierre
    Brochet, Bruno
    Sedel, Frederic
    Pelletier, Jean
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (13) : 1719 - 1731
12345